Date: 2015-07-20
Type of information: Nomination
Compound:
Company: Ultragenyx Pharmaceutical (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases - Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 20, 2015, Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced it has appointed John Pinion as Chief Quality Operations Officer and Senior Vice President, Analytical Sciences and Research, effective July 13, 2015. In this newly created role, Mr. Pinion will be responsible for the overall quality operations and analytical sciences, including Quality management of all GxP, Compliance, Validation, QC GMP, QC Clinical and QC Research. Mr. Pinion will also participate in translational research, business development, and strategic planning activities as a key member of Ultragenyx\'s executive leadership team. He will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx\'s CEO. Mr. Pinion has over 25 years of global experience providing executive leadership and expertise in quality and manufacturing management of biologic, pharmaceutical, and device operations in Asia, Europe, and the Americas. He joined Genentech in 2005 as the Vice President of External Quality and held roles with increasing responsibilities including his most recent position as the Senior Vice President and Global Head of Quality and Compliance for Roche/Genentech Pharma Technical Operations. He was responsible for all Biotech and Pharmaceutical Quality and GMP compliance activities across Europe, Asia, and the Americas. Prior to joining Genentech, Mr. Pinion held several executive positions for Baxter International both domestically and abroad, in global quality and manufacturing environments including Vice President, Quality, Renal, Cellular Therapies, Baxter Japan and Vice President, Quality North American Operations, Baxter BioScience. He holds a Bachelor of Science in Mechanical Engineering from the University of West Virginia.
Financial terms:
Latest news:
